USPTO favorable to Ceylad

March 16, 2017 Off By Dino Mustafić

The U.S. Patent and Trademark Office (USPTO) has been favorable to Ceylad for the fourth time for production of Allogenic TCR-Deficient CAR-T cells.

USPTO said there was no need to reexamine Ceylad’s U.S. patent for allogenic human primary T-cells.

Ceylad announced this on Thursday, noting that the patent remains valid and enforceable.

“ This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches and it places Celyad in a very good position to optimize the significant potential of its allogeneic platform, either on our own or through strategic collaborations”, said Christian Homsy, CEO of Celyad.

Celyad, a clinical-stage biopharmaceutical company focused on the development of specialized cell based therapies, uses its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR-2, has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and feasibility of CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase I study was successfully completed in September 2016.

THINK ( TH erapeutic I mmunotherapy with NK R-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).